Toggle light / dark theme

CellAge: Senescent Cell Targeting Technology Video

Synthetic biology meets senolytics at Lifespan.io

We are developing tools to help researchers accurately target and remove dysfunctional cells in the body that have entered a state called “senescence”, and thereby assist in restoring it to youthful functionality. Please subscribe, share, and fund our campaign today! ►Campaign Link: https://www.lifespan.io/campaigns/cellage-targeting-senescen…c-biology/ ►Subscribe: https://www.youtube.com/user/LifespanIO?sub_confirmation=1


Our society has never aged more rapidly – one of the most visible symptoms of the changing demographics is the exponential increase in the incidence of age-related diseases, including cancer, cardiovascular diseases and osteoarthritis. Not only does aging have a negative effect on the quality of life among the elderly but it also causes a significant financial strain on both private and public sectors. As the proportion of older people is increasing so is health care spending. According to a WHO analysis, the annual number of new cancer cases is projected to rise to 17 million by 2020, and reach 27 million by 2030. Similar trends are clearly visible in other age-related diseases such as cardiovascular disease. Few effective treatments addressing these challenges are currently available and most of them focus on a single disease rather than adopting a more holistic approach to aging.

Recently a new approach which has the potential of significantly alleviating these problems has been validated by a number of in vivo and in vitro studies. It has been demonstrated that senescent cells (cells which have ceased to replicate due to stress or replicative capacity exhaustion) are linked to many age-related diseases. Furthermore, removing senescent cells from mice has been recently shown to drastically increase mouse healthspan (a period of life free of serious diseases).

Here at CellAge we are working hard to help translate these findings into humans!

CellAge: Dr. Aubrey de Grey Endorsement Video

Dr. Aubrey de Grey from the SENS Research Foundation was kind enough to talk in support of CellAge and their campaign on Lifespan.io

We are developing tools to help researchers accurately target and remove dysfunctional cells in the body that have entered a state called “senescence”, and thereby assist in restoring it to youthful functionality. Please subscribe, share, and fund our campaign today! ►Campaign Link: https://www.lifespan.io/campaigns/cellage-targeting-senescen…c-biology/ ►Subscribe: https://www.youtube.com/user/LifespanIO?sub_confirmation=1


Our society has never aged more rapidly – one of the most visible symptoms of the changing demographics is the exponential increase in the incidence of age-related diseases, including cancer, cardiovascular diseases and osteoarthritis. Not only does aging have a negative effect on the quality of life among the elderly but it also causes a significant financial strain on both private and public sectors. As the proportion of older people is increasing so is health care spending. According to a WHO analysis, the annual number of new cancer cases is projected to rise to 17 million by 2020, and reach 27 million by 2030. Similar trends are clearly visible in other age-related diseases such as cardiovascular disease. Few effective treatments addressing these challenges are currently available and most of them focus on a single disease rather than adopting a more holistic approach to aging.

Recently a new approach which has the potential of significantly alleviating these problems has been validated by a number of in vivo and in vitro studies. It has been demonstrated that senescent cells (cells which have ceased to replicate due to stress or replicative capacity exhaustion) are linked to many age-related diseases. Furthermore, removing senescent cells from mice has been recently shown to drastically increase mouse healthspan (a period of life free of serious diseases).

Here at CellAge we are working hard to help translate these findings into humans!

Senescent cells accumulate with age and gradually poison their neighboring cells and secrete signals that shut down your stem cells and reduce your ability to regenerate tissue

Cellular senescence is a complicated process but here it is explained in a simple infographic. The removal of senescent cells (senolytics) is a very hot topic right now and it represents the arrival of the first of the SENS therapies.

CellAge is one of the companies engaged in senolytic research and they are running a campaign on Lifespan.io if you would like to learn more about them.

https://www.lifespan.io/campaigns/cellage-targeting-senescen…c-biology/


Lifespan.io / Life Extension Advocacy Foundation

@lifespanio

First approved targeted therapy for Gastric Cancer in Singapore offers new way and hope of treating disease

Lilly announced today that CYRAMZA® (ramucirumab) has been approved by the Singapore Health Sciences Authority to treat people with advanced gastric cancer, whose cancer has progressed after prior chemotherapy. First country in ASEAN to approve the new biologic therapy that extends survival in patients with advanced stomach cancer after prior chemotherapy

CYRAMZA® (ramucirumab) is now available to Singaporeans living with advanced gastric cancer. The drug gained approval by Singapore’s Health Science’s Authority (HSA) earlier this year, marking the first regulatory approval in ASEAN. CYRAMZA is already available to patients in Japan, Korea, Taiwan and Hong Kong.

Why Machines Should Go To The University of Google, School of Artificial Intelligence

Now that’s an idea; education for systems. I can see the online university advertisements now showing an autonomous car beeping and flashing its lights over the enjoyment of graduating.


What if I told you to tie your shoes, but you had no laces? Or to cook dinner, but you had no pots or pans.

There are certain tools we need to succeed, which we often don’t have access to or are held back by a gatekeeper.

Dozens of AI / Machine Learning startups experience this same problem because they don’t have enough data to properly train their AI algorithm. Startups that aim to eliminate the error involved in judging cancerous tumors. Startups that aim to improve personalized medicine and create a healthier future.

The power of polymeric coating

Nice write on polymeric coatings as a material option consider when developing implants replicating a natural electrode charge without creating damage or disruptions. Author proposes such materials could be leveraged beyond their use today and expanded to include BMI implants. Definitely, will take a closer look at.


Jeff Hendricks Biotectix outlines how polymeric coatings can help improve the performance of medical and consumer electronic devices.

Potential diabetes therapy: Engineered cells that control blood sugar

Excellent. Now, the question is “has Microsoft seen this?” as they are working on solving Diabetes too as part of their Synbio program that has already shown us their DNA Data Storage.


People with type 1 diabetes must inject themselves with insulin multiple times per day. This is because their immune system has destroyed cells in the pancreas that secrete insulin to maintain a healthy blood glucose level.

A team of bioengineers now report a possible alternative to such injections. The researchers engineered human kidney cells to act like pancreatic β cells, namely to sense blood glucose levels and produce insulin accordingly (Science 2016, DOI: 10.1126/science.aaf4006). When implanted in mice with type 1 diabetes, the cells prevent high blood glucose levels, also known as hyperglycemia.

Right now, “all we offer diabetic patients to cope with their disease is to have them measure their blood glucose levels and then inject a hormone,” says Martin Fussenegger of the Swiss Federal Institute of Technology, Zurich, who led the team that engineered the cells. Although this works, he says, getting the dose right can be tough. “We set out to pioneer a new disease treatment concept.”

A New Form of Synaptic Plasticity in Pain Pathways

Nice.


Chronic pain is thought to involve the long-lasting strengthening of synapses, akin to what happens during the formation of new memories. This phenomenon, known as long-term potentiation (LTP), is triggered when neurons on both sides of a synapse are active at the same time. But now, Jürgen Sandkühler, Medical University of Vienna, Austria, and colleagues provide evidence that LTP in nociceptive circuits arises in a different way.

By simultaneously activating two types of glial cells―astrocytes and microglia―the researchers were able to produce LTP at synapses that connect peripheral C-fibers and lamina I neurons in the dorsal horn spinal cord. They also showed that with high-frequency stimulation of C-fibers, glial cells strengthen active and inactive synapses through their release of the NMDA receptor co-agonist D-serine and the cytokine tumor necrosis factor (TNF). Moreover, these molecules traveled to distant synapses, perhaps explaining why pain hypersensitivity can develop in areas surrounding or far away from an injury.

“This paper is going to stimulate a lot of discussion that will lead to important advances for all of us in the pain field,” said Theodore Price, The University of Texas at Dallas, US, who was not involved in the study. “It raises questions for my lab in our day-to-day research that we can address immediately. That’s ultimately the true measure of a really good paper.”

/* */